The bacterium Aeromonas salmonicida ssp. achromogenes (Asa) causes atypical furunculosis in salmonids that may lead to extensive financial losses in intensive fish farming. The commercially available vaccine commonly used against the ssp. achromogenes in the production of Arctic charr in Iceland has been developed for Atlantic salmon (Salmon salar) against the subspecies salmonicida which causes typical furunculosis, but it has insufficient efficacy in Arctic charr. In response to this, a novel vaccine against Asa in Arctic charr was developed in cooperation with Spanish vaccine company; HIPRA, and the antibody response of Arctic charr against Asa investigated using enzyme-linked immunosorbent assay. Fish used for testing were vaccinated using the novel, monovalent autogenous experimental vaccine and a commercially available vaccine Alpha Ject® 3000 developed for Atlantic salmon that was used as a comparison. The study was conducted in commercial production units where the fish were continually exposed to natural outbreaks of atypical furunculosis. Blood samples were collected from the fish prior to vaccination and thereafter at approximately ten-week intervals in each production unit throughout the production period until the fish reached harvesting size. Fish growth and mortality was recorded throughout the study. The results indicated that both vaccines induced antibody response in fish against Asa antigens and that antibody titers obtained during the first weeks following vaccination were maintained throughout the production period. However, significantly higher antibody titers were observed in fish vaccinated with the experimental novel vaccine and fish mortality was significantly lower in production units containing fish vaccinated with the novel vaccine in comparison to the Alpha Ject 3000® vaccine. These results suggest that the novel vaccine may be a promising candidate for protective immunity against atypical furunculosis caused by Asa in Arctic charr.